Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has pleaded guilty to drug safety violations. According to a story in the New York Times, the company will pay $500 million in fines over allegations that it sold subpar drugs.
Company officials also allegedly made false statements to the U.S. Food and Drug Administration about manufacturing practices at two factories in India.
Daiichi Sankyo has faced other allegations recently concerning its medications.
Two clinical ...continue reading...